For a human T-cell xenograft experiment in the NSG model, we used 2Gy TBI. Despite a 24 hour delay of T-cell transfer post TBI to ameliorate inflammation and potential GvHD, we observed profound splenomegaly in addition to clear behavioural indications of GvHD at experimental termination 2 weeks post T-cell transfer. Had we continued along this experimental vein, we would have considered reducing the TBI dosage to 1 Gy for subsequent models. T-cell dose used was 4x10^6 transgenic T-cells/animal.